VETRIS CV included all patients with diabetes and ACD and found that SGLT2 only reduced the hospitalization rate of HF and had no obvious benefit for cardiovascular events, such as MACEs, CV death, and MI (22). This evidence concerns the gene SLC5A2 and hydrops fetalis.